Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Opus Genetics, Inc.NASDAQ: IRD

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 99.4%

Gross margin was 99.4% in Q1 FY2026, down 0.6 pp from a year earlier. On a trailing-twelve-month basis it was 49.6%, up 6.6 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
99.4%-0.6 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
49.6%+6.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.6 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's LTM Mar 2026 gross margin of 49.6% is the 3rd highest of the 6 companies compared; the peer median is 48.3%.
  • Its year-over-year change of +6.6 pp is the 3rd highest of 5, against a peer median of +9.3 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +4.6 pp.
IRD Competitors Peer median
Gross Margin for IRD and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
AGENAgenus Inc.LTM Mar 202652.1% +86.4 pp+130.9 pp
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
SEERSeer, Inc.LTM Mar 202648.3% +18.6 pp+9.2 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
HURATuHURA Biosciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
TILInstil Bio, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding IRD) 48.3%+9.3 pp+4.6 pp

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue589K39.85M19.05M10.99M14.2M
Cost of Revenue00000
Gross Profit589K39.85M19.05M10.99M14.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development15.17M14.36M17.65M26.85M30.81M
Selling, General & Admin8.12M7.27M11.96M18.22M21.98M
Operating Expenses23.29M21.62M29.61M73.07M52.8M
Depreciation & Amortization4K4K6K10K53K
EBITDA(56.69M)18.22M(9.97M)(57.52M)(48.07M)
EBITDA Margin-9624.3%45.7%-52.3%-523.3%-338.6%
Operating Income(22.71M)18.23M(10.56M)(62.07M)(38.6M)
Operating Margin-3854.8%45.7%-55.5%-564.7%-271.9%
Interest Income00000
Interest Expense2K9K1.33M01.47M
Other Income / Expenses(33.99M)(23K)589K4.54M(10.99M)
Income Before Tax(56.69M)18.2M(9.97M)(57.53M)(49.59M)
Pre-Tax Margin-9625.3%45.7%-52.4%-523.4%-349.3%
Income Tax Expense0315K12K00
Net Income(56.69M)17.89M(9.99M)(57.53M)(49.59M)
Net Margin-9625.3%44.9%-52.4%-523.4%-349.3%
EPS (Basic)(3.82)0.90(0.46)(2.15)(0.80)
EPS (Diluted)(3.82)0.87(0.46)(2.15)(0.80)
Weighted Avg Shares14.85M19.93M21.59M26.72M622.22M
Weighted Avg Shares (Diluted)14.85M20.6M21.59M26.72M622.22M

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.